Sograzepide
| Title | Journal |
|---|---|
| Regulated endocrine-specific protein 18 (RESP18) is localized to and regulated in A-like cells and G-cells in rat stomach. | Regulatory peptides 20120820 |
| Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. | Alimentary pharmacology & therapeutics 20120701 |
| JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. | The Journal of pharmacology and experimental therapeutics 20110701 |
| The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. | Regulatory peptides 20100608 |
| Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer. | European journal of cancer (Oxford, England : 1990) 20090201 |
| Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template. | Bioorganic & medicinal chemistry 20080315 |
| A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. | Regulatory peptides 20071004 |
| Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion. | Journal of medicinal chemistry 20070628 |
| Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways. | American journal of physiology. Gastrointestinal and liver physiology 20070601 |
| Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors. | Journal of medicinal chemistry 20060406 |
| Gastrin increases murine intestinal crypt regeneration following injury. | Gastroenterology 20060401 |
| Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. | Gastroenterology 20050601 |
| Secretory organelles in ECL cells: effects of pharmacological blockade of the gastrin/CCK2 receptor versus its elimination by gene targeting. | Inflammopharmacology 20050101 |
| CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. | Scandinavian journal of gastroenterology 20040901 |
| Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020605 |
| Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor. | Regulatory peptides 20020115 |
| Gastric acid secretion in L-histidine decarboxylase-deficient mice. | Gastroenterology 20020101 |
| Effects of CCK2 receptor blockade on growth parameters in gastrointestinal tract and pancreas in rats. | Pharmacology & toxicology 20011001 |
| Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats. | British journal of pharmacology 20010501 |
| Carbon-11 labelled cholecystokininB antagonists: radiosynthesis and evaluation in rats. | Life sciences 20010202 |
| YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. | Alimentary pharmacology & therapeutics 19970201 |
| (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. | Journal of medicinal chemistry 19970131 |